108 related articles for article (PubMed ID: 22177649)
21. Aprepitant for pruritus: drug-drug interactions matter.
Mir O; Coriat R
Lancet Oncol; 2012 Oct; 13(10):964-5. PubMed ID: 22995652
[No Abstract] [Full Text] [Related]
22. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
Smith AR; Repka TL; Weigel BJ
Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
[TBL] [Abstract][Full Text] [Related]
23. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
24. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
25. The use of aprepitant in brachioradial pruritus.
Ally MS; Gamba CS; Peng DH; Tang JY
JAMA Dermatol; 2013 May; 149(5):627-8. PubMed ID: 23677105
[No Abstract] [Full Text] [Related]
26. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
27. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
[TBL] [Abstract][Full Text] [Related]
29. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
30. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
31. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
32. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Hargreaves R; Ferreira JC; Hughes D; Brands J; Hale J; Mattson B; Mills S
Ann N Y Acad Sci; 2011 Mar; 1222():40-8. PubMed ID: 21434941
[TBL] [Abstract][Full Text] [Related]
33. Aprepitant in refractory pruritus of systemic lymphoproliferative disorders.
Pulido-Perez A; Carretero-Lopez F; Bergon-Sendin M; Nieto-Benito LM; Romero-Jimenez R; Dorado-Herrero N; Bastos-Oreiro MB; Suárez-Fernández R
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e422-e424. PubMed ID: 32180276
[No Abstract] [Full Text] [Related]
34. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
Green SA; Alon A; Ianus J; McNaughton KS; Tozzi CA; Reiss TF
J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous lymphosarcoma and leukemia in a cat.
Schick RO; Murphy GF; Goldschmidt MH
J Am Vet Med Assoc; 1993 Oct; 203(8):1155-8. PubMed ID: 8244863
[TBL] [Abstract][Full Text] [Related]
37. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.
Rodgers J; Bradley B; Kennedy PG
Parasitol Int; 2007 Dec; 56(4):321-4. PubMed ID: 17643344
[TBL] [Abstract][Full Text] [Related]
39. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
40. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.
Young TA; Patel TS; Camacho F; Clark A; Freedman BI; Kaur M; Fountain J; Williams LL; Yosipovitch G; Fleischer AB
J Dermatolog Treat; 2009; 20(2):76-81. PubMed ID: 18821119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
